Trial Profile
A Phase I/II Study of Regorafenib and Pembrolizumab in Metastatic Colorectal Cancer Patients in 3rd and 4th Line Setting
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Feb 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Feb 2023 Planned End Date changed from 21 Jun 2024 to 21 Jun 2025.
- 15 Feb 2023 Planned primary completion date changed from 21 Jun 2023 to 21 Jun 2024.
- 05 Aug 2022 Planned End Date changed from 21 Jun 2023 to 21 Jun 2024.